{
    "organizations": [],
    "uuid": "7dc36d6e1c2daee8957967ebe02da660adbfb6a6",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-basilea-pharmaceutica-reports-clin/brief-basilea-pharmaceutica-reports-clinical-phase-3-study-start-with-antibiotic-ceftobiprole-in-skin-infections-idUSFWN1QC1G1",
    "ord_in_thread": 0,
    "title": "BRIEF-Basilea Pharmaceutica Reports Clinical Phase 3 Study Start With Antibiotic Ceftobiprole In Skin Infections",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 23 (Reuters) - BASILEA PHARMACEUTICA AG:‍​\n* REPORTS CLINICAL PHASE 3 STUDY START WITH ANTIBIOTIC CEFTOBIPROLE IN SKIN INFECTIONS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-23T14:18:00.000+02:00",
    "crawled": "2018-02-23T08:24:48.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "basilea",
        "pharmaceutica",
        "ag",
        "report",
        "clinical",
        "phase",
        "study",
        "start",
        "antibiotic",
        "ceftobiprole",
        "skin",
        "infection",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}